纳米制剂克服肿瘤多药耐药的研究进展  

Research progress on nanomedicine overcoming tumor multidrug resistance

作　　者：匡正 秦超[1] 杨磊 尹莉芳[1] 韩晓鹏 KUANG Zheng;QIN Chao;YANG Lei;YIN Lifang;HAN Xiaopeng(School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学药学院,江苏南京211198

出　　处：《药学研究》2022年第10期667-672,696,共7页Journal of Pharmaceutical Research

基　　金：国家科技重大专项“重大新药创制”项目(No.2017ZX09101001-004)。

摘　　要：多药耐药性是肿瘤治疗的重要障碍,而靶向性、协同载药能力等功能使纳米制剂成为克服肿瘤多药耐药的理想载体。本文首先介绍了多药耐药性的主要产生机制,然后着重介绍了基于抑制外排、诱导细胞程序性死亡的多功能纳米制剂,用于逆转肿瘤多药耐药性的研究进展,以期为耐药性肿瘤治疗提供思路和方法。For cancer treatment,multidrug resistance(MDR)is an important obstacle.The excellent functions of nanomedicine,such as targeting and co-delivery of drugs,make it a good carrier of overcoming MDR.This paper introduced main mechanisms of MDR,focusing on the design of nanomedicine to overcome MDR with the guidance of inhibiting efflux,inducing programmed cell death,and reversing multidrug resistance by targeting tumor micro-environment.This paper provided reference for the treatment of drug-resistant tumors.

关 键 词：纳米制剂 肿瘤 多药耐药 

分 类 号：R730.5[医药卫生—肿瘤]